{"nctId":"NCT00939900","briefTitle":"Efficacy of Zoledronic Acid in Preventing Collapse of the Osteonecrotic Femoral Head","startDateStruct":{"date":"2009-07"},"conditions":["Avascular Necrosis of Femoral Head"],"count":110,"armGroups":[{"label":"aclasta","type":"EXPERIMENTAL","interventionNames":["Drug: zoledronic acid (aclasta)"]},{"label":"control","type":"NO_INTERVENTION","interventionNames":[]}],"interventions":[{"name":"zoledronic acid (aclasta)","otherNames":["aclasta"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patient who agree to clinical trial\n* Patient who are more than 18 years of age\n* Osteonecrosis of the femoral head\n* Steinberg stage I, II non traumatic osteonecrosis of femoral head\n* Necrotic area of \\> 30% (HJ Kim et al )\n* JIC (Japanese Investigation Committee): C1 or C2 lateral lesion (by X-ray or MRI)\n\nExclusion Criteria:\n\n* Patients who are pregnant (patients who are of child bearing potential who are not practicing a reliable contraceptive method (oral, subcutaneous, mechanical, or surgical contraception)\n* Patients who have contraindicated condition to zoledronic acid such as chronic renal failure (calculated creatinine clearance less than 35.0 ml/min), severe heart disease such as atrial fibrillation, sensitive to bisphosphonates and hypocalcemia (serum calcium less than 8 mg/dl or 2.0 mmol/L)\n* Patients who have collapsed lesion including subchonral fracture\n* Patients who have multiple lesion of osteonecrosis of femoral head\n* Patients who received other kinds of bisphophonates or anabolic agents before zoledronic acid use\n* Patients with any medical or psychiatric condition which, in the Investigator's opinion would preclude the participant from adhering to the Protocol or completing the trial per protocol\n* Patients who are considered potentially unreliable and patients who may not reliably attend study visits","healthyVolunteers":false,"sex":"ALL","minimumAge":"19 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Femoral Head Collapse Within 24 Months","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"22","spread":null}]}]}]},{"type":"SECONDARY","title":"Collpase Rate of Femoral Head","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Change of HHS (Harris Hip Scores), WOMAC Score, SF-36","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Time to Collapse of Femoral Head","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Time to Total Arthroplasty or Joint Preserving Surgery","description":null,"paramType":null,"dispersionType":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":55},"commonTop":[]}}}